Setting Up or Sourcing a Pharma Business in Dubai: What Actually Matters

The single most expensive mistake people make when trying to get into pharma in Dubai is setting up in the wrong jurisdiction. A free-zone pharmaceutical trading company cannot sell directly to a Dubai hospital, pharmacy chain, or clinic — it can import, warehouse and re-export, but the moment a product needs to reach a local buyer, it has to pass through a mainland-licensed distributor. This trips up a lot of first-time entrants who set up in a free zone because it looked cheaper and faster, then discover six months later they need a second entity, or a local agent agreement, just to sell into the market they came here for.

Mainland or free zone decides who you're allowed to sell to

If the plan is to distribute registered drugs, medical devices or supplements to UAE pharmacies, hospitals or clinics, you need a mainland trading license from the DED, plus a no-objection certificate and facility approval from the Ministry of Health and Prevention (MOHAP), which regulates pharmaceuticals federally. Dubai's own health authority, the DHA, separately licenses pharmacies, clinics and healthcare practitioners operating inside the emirate — the two bodies overlap but aren't interchangeable, and a distributor should be able to tell you clearly which approvals it holds and from which authority.

Free zones still have a role. Dubai Healthcare City (DHCC) suits companies focused on clinical partnerships, medical education or device distribution to hospitals within its own cluster. Jebel Ali Free Zone (JAFZA) and Dubai South are the two most common bases for pharma logistics and re-export operations, largely because of proximity to the port and airport and the cold-chain warehousing already built out in those areas. If your business model is regional distribution — using Dubai as a hub to reach Saudi Arabia, Iraq or East Africa — a free zone plus bonded warehousing is usually the right structure. If your business model is selling into the UAE retail or hospital market, it isn't.

What MOHAP drug registration actually costs and how long it takes

Every pharmaceutical product sold in the UAE, regardless of where the distributor is based, needs to be registered with MOHAP before it can legally be sold. This is the part people underestimate. A straightforward generic registration typically runs 20,000–45,000 AED in government fees and dossier preparation once you include a registration consultant, and takes anywhere from nine to eighteen months from submission to approval — longer for novel formulations or anything requiring additional clinical data. Anyone who tells you they can register a new drug in eight weeks either doesn't understand the process or is quoting you for something else, such as a supplement or medical device registration, which follows a lighter and faster track.

Foreign manufacturers without a UAE presence need a locally registered agent to submit and hold the registration on their behalf — this is a legal requirement, not a convenience. That agent relationship should be documented in a formal distribution or agency agreement specifying territory, exclusivity, minimum order commitments and what happens to the registration if the relationship ends. Registrations are held by the local agent, not the manufacturer, which means switching distributors later is far more painful than it sounds. Get the agreement checked by a UAE healthcare regulatory lawyer before signing, not after a dispute starts.

Where the trade actually sits geographically

Al Quoz and Ras Al Khor host most of Dubai's temperature-controlled pharma warehousing — older industrial stock retrofitted with cold rooms, alongside newer purpose-built cold-chain facilities. Dubai South and JAFZA carry the larger-scale, airport- and port-adjacent logistics operations aimed at re-export. DHCC remains the address of choice for companies whose business is genuinely clinical — device reps, CRO offices, specialist distributors working directly with hospitals in that free zone. If a distributor claims to run serious cold-chain storage but operates out of a small mainland office with no visible warehouse, ask to see the facility. Good Distribution Practice (GDP) certification requires validated temperature monitoring, and any distributor handling biologics or vaccines should be able to produce that certificate on request, not promise to email it later.

Questions that expose an unqualified partner

A properly set up pharma distributor or registration agent should answer all of the following without hesitation:

• Which MOHAP and DHA licenses do you hold, and can I see the license numbers to verify them directly with the authority?
• Do you hold current GDP certification for the products you'd be handling, and when was your last audit?
• Who owns the drug registration once it's granted — you, or the manufacturer — and what's the exit clause if we end the agreement?
• Can I visit the warehouse and see the temperature-monitoring logs, not just the certificate?
• What's your typical timeline and total cost breakdown for a registration of this product category, itemised rather than quoted as a lump sum?

Vague answers to the first two questions are the clearest warning sign. Distributors that talk fluently about margins and market access but go quiet on licensing detail are common enough in Dubai's pharma-adjacent trading scene, particularly around supplements and cosmeceuticals, which sit in a regulatory grey zone with lighter registration requirements than medicines. That's fine if you know that's the category you're in — it's a problem if you were told your product would go through as a supplement to save time when it's actually a scheduled medicine.

What a fair quote actually contains

A distribution or registration proposal worth signing itemises government fees separately from consultant or agency fees, states a realistic timeline in months rather than weeks, and specifies who is legally the MOHAP registration holder. Distributor margins on pharmaceuticals in the UAE typically sit between 15% and 30% depending on product category and volume commitment — anything markedly outside that range deserves an explanation. Setup costs for a mainland pharma trading license, including DED registration, MOHAP facility approval and initial office lease, generally land between 35,000 and 70,000 AED depending on warehouse requirements, with DHA-regulated activities such as running an actual pharmacy counter adding a separate and more demanding licensing layer on top. None of this moves quickly, and anyone promising otherwise is telling you what you want to hear rather than what the ministry actually requires.